Loading organizations...
SaNOtize is a global pharmaceutical company that developed a disruptive, first-in-class technology to deliver the natural antimicrobial properties of nitric oxide (NO) for the first time.
SaNOtize has raised $27.0M across 2 funding rounds.
SaNOtize has raised $27.0M in total across 2 funding rounds.
SaNOtize has raised $27.0M in total across 2 funding rounds.
SaNOtize's investors include OurCrowd, Frances Kang, Azolla Ventures, 91 Ventures, lool ventures.
SaNOtize has raised $27.0M across 2 funding rounds. Most recently, it raised $24.0M Series B in August 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Aug 1, 2022 | $24M Series B | OurCrowd, Frances Kang | Azolla Ventures | Announced |
| Mar 1, 2020 | $3M Series A | — | 91 Ventures, Lool Ventures, OurCrowd | Announced |
SaNOtize is a Vancouver-based biotechnology company developing products that harness nitric oxide (NO) for topical antimicrobial applications against viral, bacterial, and fungal infections.[2][1][3] Its flagship product, an antiviral Nitric Oxide Nasal Spray (branded as VirX™, enovid™, or FabiSpray), targets upper respiratory infections including all COVID-19 variants, reducing viral RNA load by over 95% in 24 hours and 99% in 72 hours in clinical studies.[5] The company serves consumers and high-risk patients via medical device approvals in multiple countries and a prescription drug in India, solving antimicrobial resistance by delivering NO—a natural broad-spectrum agent—topically for the first time through its patented NORS™ platform.[1][2][5][6] Growth includes hundreds of thousands of users, international launches, and planned U.S. wellness product entry in 2024 as NOWONDER Nasal Spray.[5]
SaNOtize was co-founded in 2017 by Gilly Regev, PhD (biochemist) and Chris Miller, PhD (NO field expert), who together invented a novel NO delivery system enabling its use as a topical antimicrobial.[2] The idea stemmed from leveraging NO's natural infection-fighting properties, previously limited by delivery challenges, to address common infections.[1][4] Early traction built through clinical validation against respiratory viruses, culminating in FabiSpray's 2021 approval in India—the first regulatory nod for NO as an antimicrobial therapeutic—and subsequent device registrations in Israel, Germany, South Africa, and Asia.[5]
SaNOtize rides the antimicrobial resistance crisis and post-pandemic demand for non-antibiotic virucides, where NO's natural mechanism disrupts microbes without resistance buildup.[2][3][6] Timing aligns with global regulatory shifts favoring rapid device approvals for respiratory threats, amplified by COVID validation.[5] Market forces like rising viral outbreaks and wellness trends favor its scalable, over-the-counter potential, influencing biotech by proving NO platforms can accelerate from lab to market.[4][5] It contributes to the ecosystem by licensing tech and expanding NO's role in infection control.
SaNOtize's NORS™ positions it for expansion into U.S. wellness (NOWONDER in 2024) and Phase III trials (e.g., rhinosinusitis), potentially unlocking larger indications like influenza prevention.[3][5] Trends in resistance and at-home antivirals will propel growth, with influence evolving via partnerships and pipeline diversification. As a pioneer in NO therapeutics, it exemplifies biotech agility, building on COVID momentum to redefine topical antimicrobials.[2][4]
